GTC
ACAD icon

Ghost Tree Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Ghost Tree Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-207,200
Closed -$7.12M – 67
2017
Q1 		$7.12M Buy
+207,200
New +$7.31M 1.33% 33
2016
Q2 		– Sell
-350,000
Closed -$9.79M – 66
2016
Q1 		$9.79M Buy
+350,000
New +$7.63M 5.54% 2

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Ghost Tree Capital's ACAD Position: Q3 2024 in Review

Ghost Tree Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 225,000 shares — an estimated $3.66M sold.

Ghost Tree Capital first reported a position in ACAD in Q1 2015 and held it in 18 quarters. The position peaked at $24.2M in Q1 2019. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Ghost Tree Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 225,000 Acadia Pharmaceuticals shares in Q3 2024, an estimated $3.66M.
  • Ghost Tree Capital first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 18 quarters.
  • Ghost Tree Capital's Acadia Pharmaceuticals position peaked at $24.2M in Q1 2019.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.